Related Experiment Videos
Prolyl endopeptidase inhibitors
1CHINOIN Pharmaceutical and Chemical Works Ltd., Budapest, Hungary. istvan.hermecz@sanofi-synthelabo.com
Farmaco (Societa Chimica Italiana : 1989)
|August 5, 2000
Summary
Selective prolyl endopeptidase inhibitors were developed using computational and structural methods. These novel compounds show potent activity in vitro and significant effects in vivo.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Structural Biology
Background:
- Prolyl endopeptidase (PEP) is a target enzyme implicated in various physiological and pathological processes.
- Existing inhibitors may lack optimal potency or selectivity.
- Structure-based drug design offers a rational approach to developing novel inhibitors.
Purpose of the Study:
- To design and synthesize novel selective prolyl endopeptidase inhibitors.
- To optimize inhibitor potency and pharmacokinetic properties through structural modifications.
- To explore the structure-activity relationships of a new class of PEP inhibitors.
Main Methods:
- Utilized Comparative Molecular Field Analysis (CoMFA) for quantitative structure-activity relationship (QSAR) modeling.
- Employed protein crystallography to elucidate the binding mode of inhibitors within the enzyme's active site.
- Synthesized and characterized omega-(N-hetaryl)alkanoylprolylpyrrolidine derivatives.
Main Results:
- Identified key structural features contributing to high inhibitory activity.
- Achieved potent inhibition with IC50 values in the nanomolar to picomolar range (10^-9 to 10^-11 M).
- Demonstrated significant in vivo efficacy of the most promising compounds.
Conclusions:
- The modified omega-(N-hetaryl)alkanoylprolylpyrrolidines represent a promising class of selective prolyl endopeptidase inhibitors.
- The combination of CoMFA and protein crystallography was effective in guiding the optimization process.
- These findings support the potential therapeutic application of these inhibitors in relevant disease models.